A Next-Generation Single-Port Robotic Surgical System for Transoral Robotic Surgery

Abstract

IMPORTANCE Transoral endoscopic head and neck surgery now plays an important role in the multidisciplinary management of oropharyngeal carcinoma. Previous generations of robotic surgical systems used a multiport system with a rigid stereo-endoscope and 2 wristed instruments that facilitated transoral robotic surgery.OBJECTIVE To evaluate a new single-port robotic surgical system in head and neck surgery prospectively through concurrent nonrandomized clinical trials. DESIGN, SETTING, AND PARTICIPANTS Two prospective clinical trials were conducted from December 16, 2016, to December 26, 2017, to assess the safety, feasibility, and performance of a flexible single-port robotic surgical system in 4 institutions, including 3 in the United States and 1 in Hong Kong. A total of 47 patients with tumors of the oropharynx were enrolled and underwent surgery. All patients were classified as having American Society of Anesthesiologists class I to III status and Eastern Cooperative Oncology Group status 0 to 1. An initial cohort of 7 patients underwent staging and endoscopic procedures for benign disease. The remaining 40 patients all had malignant tumors of the oropharynx.MAIN OUTCOMES AND MEASURES Safety was measured by the incidence of device-related serious adverse events. Feasibility and performance were measured by the conversion rate from the use of the single-port robotic surgical system to either open surgery or the use of any other transoral technology required to complete the planned procedure. Secondary end points of swallowing function and surgical margins were also measured. RESULTSAll 47 patients (8 women and 39 men; mean [SD] age, 61 [8] years) safely underwent transoral resection with the single-port robotic surgical system without conversion to open surgery, laser surgery, or multiport robotic surgery. There were no intraoperative complications or device-related serious adverse events. Mean (SD) estimated intraoperative blood loss per procedure was 15.4 (23.9) mL; no patients received a transfusion. Two patients underwent a planned tracheotomy owing to medical comorbidity (previous chemoradiotherapy; obesity and severe sleep apnea). Two patients (4%) had grade III or IV postoperative hemorrhage, requiring a return to the operating room; however, both patients had medical comorbidities requiring the use of antithrombotic medication. The incidence of positive margins for patients with oropharyngeal malignancy was 3% (1 of 40). Within 30 days, 45 patients (96%) were eating by mouth and without the need for a percutaneous endoscopic gastrostomy tube.CONCLUSIONS AND RELEVANCE This study describes the results of phase 2 clinical testing of a next-generation, robotic surgical system using a single-port architecture. The use of the device appears to be feasible, safe, and effective for transoral robotic surgery of oropharyngeal tumors. TRIAL REGISTRATION ClinicalTrials.gov identifiers: NCT03010813 and NCT03049280

Current Advances in Robotics for Head and Neck Surgery—A Systematic Review

“…Several clinical trials describe successful procedures on a total of 88 patients with oropharynx cancers [ 21 , 22 ]. Advantages in comparison to the preceding model can be seen in improved visualization and a revised surgical instrument handling.…”

<p>Novel Energy Devices in Head and Neck Robotic Surgery – A Narrative Review</p>

“…A similar study encompassing the previous Hong Kong cohort, in addition to three US centers, evaluated 47 patients undergoing TORS with the da Vinci SP. 62 40 of these patients had cancer. There were no intra-operative complications and intra-operative blood loss was minimal.…”

Lasers and Robots: Recent Developments in Transoral Laser and Transoral Robotic Surgery

“…The SP-R is composed of a smaller highly articulated endoscope and three similar-sized reconfigurable robotic arms. 36,37 Both robotic systems have undergone clinical studies and have been proven effective for diagnostic and transoral cancer surgery. 34,36,37 These robotic systems used for TORS are currently commercially available, allowing third party institutions and medical practitioners to further study the possible add-on technologies.…”